Your Outsourced Competitive Intelligence Team
Industry expert competitive intelligence research team for pharma, biotech, and biotech investors. Advance your clinical programs and invest in novel therapeutics with the complete competitive picture.
Researching The Ever-Changing Global Competitive Landscape for Your Asset Takes Time.
Let Us Do It For You.
We dive deep on every aspect of biotech competitive intelligence:
Drug Discovery Monitoring
We track every new development that occurs globally at the discovery and preclinical stages of drug development for any published results that may affect your asset's competitive thesis.
- Publication Monitoring
- Conference Research Presentations
- Patent Filings
Clinical Trial Developments
We review all clinical trial milestones, design protocols, and results to inform your clinical trial design strategy and understand how your asset stacks up against competitors on every metric (clinical profile, launch timeline, and more).
- Data Readout Review
- Trial Protocol Analyses
- Global Registry Monitoring
Regulatory Engagement Insights
We uncover the regulatory strategy of competitors to understand what works and what doesn't for the FDA and other regulators to help speed up drug development and increase the odds of approval.
- FDA Advisory Meeting Examinations
- Evidence Package Analyses
- Regulatory Outcomes Analyses
See Our Competitive Intelligence Research
We track every indication pipeline. Check out some of our research below:
Menin Inhibitor Drug Development Landscape: Two AML Approvals and a Pipeline Eyeing Diabetes
Two menin inhibitors, revumenib and ziftomenib, reached the US market in 2024 and 2025 as the first therapies targeting the menin-KMT2A interaction in KMT2A-rearranged and NPM1-mutant leukemias. Eight additional small molecule menin inhibitors are in active clinical development, split between oncology combination regimens and an emerging application in type 2 diabetes. Every asset in the pipeline remains a small molecule inhibitor; menin degraders exist only in early discovery, positioning next-generation inhibitor combinations as the near-term answer to acquired resistance.
Read report →Ivonescimab (SMT112) in NSCLC: Independent Peak Sales Estimate
Independent bottom-up peak sales estimate for ivonescimab (SMT112) in non-small cell lung cancer (NSCLC). Ivonescimab is Akeso and Summit Therapeutics' bispecific PD-1/VEGF inhibitor, already NMPA-approved in China and now under FDA review in the US, backed by breakthrough Phase 3 HARMONi-2 data showing a 49% reduction in risk of death or progression versus pembrolizumab. While ivonescimab's initial FDA submission targets a narrow population (EGFR-mutated, nonsquamous NSCLC progressing after third-generation TKI therapy), broader NSCLC approval is highly likely by the time of peak sales given its superiority to current standard of care pembrolizumab. Our base case model reflects this broad NSCLC approval and estimates peak US sales of $6.5B and peak global sales of $11.0B. The interactive calculator allows readers to narrow the population by checking any of five clinical subgroup filters to model more conservative approval scenarios.
Read report →In Vivo CAR-T Landscape: T-cell Reprogramming Directly in Patients
In vivo CAR-T therapy aims to eliminate the cost, delay, and manufacturing burden of traditional ex vivo CAR-T by delivering CAR genetic material directly into the patient's body. Fourteen assets across ten companies are in active development, split evenly between permanent lentiviral-delivered programs chasing oncology indications and transient LNP-delivered programs chasing autoimmune disease. No therapy has yet reached the market and the furthest programs remain in phase 1, but the platform-driven nature of the space means most sponsors are advancing multiple pipeline assets in parallel, with Umoja Biopharma and CREATE Medicines emerging as the two most prolific developers.
Read report →Built on data from
FDA
ClinicalTrials.gov
PubMed
SEC EDGAR
CMS
NICE
WHO ICTRP
ICER
EMAFDAClinicalTrials.govPubMedSEC EDGARCMSNICEWHO ICTRPICEREMAFDAClinicalTrials.govPubMedSEC EDGARCMSNICEWHO ICTRPICEREMAWhy choose Inflection Labs to run your competitive intelligence?
| Inflection Labs | DIY with AI | Consulting Firm | Full Time In-House CI Hire | |
|---|---|---|---|---|
Turnaround | Within days, by combining tech & domain expertise | Minutes, but needs heavy QA | 6–12 weeks, data is already stale | Weeks to ramp up |
Biopharma depth | Deep scientific, clinical, regulatory, and commercial expertise | Surface-level, highly prone to hallucination | Deep but specialized and narrow | Dependent on hire but often deep |
Cost | From $2K per month | Low tool cost, high time cost | $50K–$200K+ | $150K+/yr salary + benefits per hire |
Data sources | FDA, CT.gov, PubMed, SEC, HTAs, Patent Repos, Conference Repos | Public web + LLM training data (including low credibility sources) | Interviews + public data | Varies |
Exec Team & Board-ready output | Yes. Polished & cited, with easily traceable source data | Needs extensive editing & fact-checking | Yes, but outputs lack adapability | Varies |
Scalability | On-demand, any volume | Fast but inconsistent quality | Per project | Limited by headcount |
Inflection Labs
Within days, by combining tech & domain expertise
DIY + AI
Minutes, but needs heavy QA
Consulting Firm
6–12 weeks, data is already stale
In-House Hire
Weeks to ramp up
Inflection Labs
Deep scientific, clinical, regulatory, and commercial expertise
DIY + AI
Surface-level, highly prone to hallucination
Consulting Firm
Deep but specialized and narrow
In-House Hire
Dependent on hire but often deep
Inflection Labs
From $2K per month
DIY + AI
Low tool cost, high time cost
Consulting Firm
$50K–$200K+
In-House Hire
$150K+/yr salary + benefits per hire
Inflection Labs
FDA, CT.gov, PubMed, SEC, HTAs, Patent Repos, Conference Repos
DIY + AI
Public web + LLM training data (including low credibility sources)
Consulting Firm
Interviews + public data
In-House Hire
Varies
Inflection Labs
Yes. Polished & cited, with easily traceable source data
DIY + AI
Needs extensive editing & fact-checking
Consulting Firm
Yes, but outputs lack adapability
In-House Hire
Varies
Inflection Labs
On-demand, any volume
DIY + AI
Fast but inconsistent quality
Consulting Firm
Per project
In-House Hire
Limited by headcount
Frequently Asked Questions
Ready to get started?
Book a 30-minute scoping call, or tell us what you need and we'll get back to you within 24 hours.
Book a Call